2025
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M. The Impact and Safety of GLP‐1 Agents and Breast Cancer. Cancer Medicine 2025, 14: e70932. PMID: 40552446, PMCID: PMC12186097, DOI: 10.1002/cam4.70932.Peer-Reviewed Original ResearchConceptsBreast cancer patientsGLP-1 receptor agonistsBreast cancerBreast cancer-specific mortalityCancer patientsBreast cancer incidenceBreast cancer ratesWeight management interventionsProportion of breast cancer patientsNon-cancer populationObese post-menopausal womenReceptor agonistsBreast cancer outcomesBreast cancer progressionWeight loss interventionWeight management strategiesEffective weight managementGLP-1Quality of lifeAll-Cause MortalityCancer-specific mortalityImprove patient outcomesObesity prevalenceWeb of ScienceCancer incidenceScreening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, PMCID: PMC12000969, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stages
2024
Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer.
Huang S, Westvold S, Soulos P, Winer E, Robinson T, Dinan M. Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer. Journal Of Clinical Oncology 2024, 20: 145-145. DOI: 10.1200/op.2024.20.10_suppl.145.Peer-Reviewed Original ResearchScreen-detected breast cancerBreast cancer mortalityScreening historyScreening mammographyScreening mammogramsCancer mortalityFee-for-service Medicare Parts ABreast cancerBreast cancer-specific mortalityScreening prior to diagnosisNon-Hispanic black raceNegative screening mammogramCohort study of womenFactors associated with increased oddsAssociated with lower riskRetrospective cohort study of womenRoutine screening mammographyMedicare Part AHigh school educationStudy of womenCancer-specific mortalityMultivariate logistic regressionSEER-Medicare databaseClaims-based algorithmSporadic screeningMortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Leone J, Hassett M, Freedman R, Tolaney S, Graham N, Tayob N, Vallejo C, Winer E, Lin N, Leone J. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. JAMA Oncology 2024, 10: 508-515. PMID: 38421673, PMCID: PMC10905378, DOI: 10.1001/jamaoncol.2023.7194.Peer-Reviewed Original ResearchBreast cancer-specific mortalityRisk of breast cancer-specific mortalityBreast cancer-specific mortality riskHR+ breast cancerBreast cancerStage I to III hormone receptor-positive breast cancerEnd Results ProgramPopulation-based dataHormone receptor-positive (HR+) breast cancerCancer-specific mortalityObservational cohort studyResults ProgramRisk of late mortalityHigher stages of diseaseHormone receptor-positive breast cancerReceptor-positive breast cancerMortality riskCohort studyRisk of distant recurrenceStage IIICumulative riskStage IIMultivariate regressionMedian Follow-UpGrade I tumors
2023
Post-diagnosis weight trajectories and mortality among women with breast cancer
Puklin L, Li F, Cartmel B, Zhao J, Sanft T, Lisevick A, Winer E, Lustberg M, Spiegelman D, Sharifi M, Irwin M, Ferrucci L. Post-diagnosis weight trajectories and mortality among women with breast cancer. Npj Breast Cancer 2023, 9: 98. PMID: 38042922, PMCID: PMC10693588, DOI: 10.1038/s41523-023-00603-5.Peer-Reviewed Original ResearchBody mass indexBreast cancer diagnosisWeight changeCause mortalityClinical characteristicsWeight gainWeight lossBreast cancerWeight trajectoriesPost-diagnosis weight changeBreast cancer-specific mortalityCox proportional hazards modelModern treatment eraCancer-specific mortalityCancer diagnosisModerate weight lossModerate weight gainProportional hazards modelAdverse health outcomesElectronic health recordsTreatment eraBaseline characteristicsTumor RegistryMass indexWeight managementEstimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool
Leone J, Graham N, Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool. European Journal Of Cancer 2023, 189: 112930. PMID: 37356327, DOI: 10.1016/j.ejca.2023.05.018.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityTriple-negative breast cancerRisk of BCSMTumor characteristicsBreast cancerCumulative riskNon-metastatic triple-negative breast cancerMost tumor characteristicsCancer-specific mortalityRisk of deathPopulation-based riskHigh-grade triple-negative breast cancerCause mortalityMost patientsPathologic variablesInitial diagnosisHigh riskNew diagnosisPatientsMortalityDiagnosisYear 0RiskCancerWomen
2022
Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study.
Check D, Jackson B, Spees L, Dinan M, Kwong J, Mehta S, Wheeler S, Wilson L, Faherty E, Reeder-Hayes K, Lam C. Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study. Journal Of Clinical Oncology 2022, 40: 399-399. DOI: 10.1200/jco.2022.40.28_suppl.399.Peer-Reviewed Original ResearchMetastatic breast cancerAnti-HER2 therapyHER2-low expressionMBC patientsEmergency departmentIHC 0Endocrine monotherapyEndocrine therapyTreatment patternsInfusion visitsCDK4/6 inhibitorsHER2 expressionBreast cancerDe novo metastatic breast cancerRetrospective population-based cohort studyNovo metastatic breast cancerBreast cancer-specific mortalityCancer-specific mortality ratesPopulation-based cohort studyHealth care resource useState cancer registry dataHormone receptorsCancer-specific mortalityHealthcare resource utilizationHormone receptor statusEstimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool
Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Leone J, Vallejo CT, Winer EP, Lin NU, Tayob N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. European Journal Of Cancer 2022, 173: 20-29. PMID: 35841843, DOI: 10.1016/j.ejca.2022.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityHR-positive breast cancerBreast cancerCumulative riskCause mortalityTumor characteristicsRisk of BCSMHormone receptor-positive breast cancerReceptor-positive breast cancerCancer-specific mortalityEnd Results registryLong-term mortalityRisk of deathCancer patient subgroupsPopulation-based riskPathologic variablesInitial diagnosisPatient subgroupsSEER dataPatientsAge groupsCancerMortalityHormone receptorsDiagnosisEpisodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.
Sukumar J, Vaughn J, Stein J, Schnell P, Sudheendra P, Pariser A, Gatti-Mays M, Williams N, Cherian M, Stover D, Wesolowski R, Ramaswamy B, Lustberg M, Sardesai S. Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors. Journal Of Clinical Oncology 2022, 40: tps12139-tps12139. DOI: 10.1200/jco.2022.40.16_suppl.tps12139.Peer-Reviewed Original ResearchPrimary endpointSecondary endpointsCancer survivorsBehavioral interventionsBody weightBreast cancer-specific mortalityDiet qualityWeight lossObese BC survivorsCancer-specific mortalityPhase II trialBreast cancer survivorsImproved diet qualityDD ratesEligible patientsHs-CRPII trialObese patientsBC survivorsAdherence ratesInsulin resistanceSpecific mortalitySurvivorship programsEpisodic future thinkingPatient engagementCardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women’s Health Initiative
Dieli-Conwright CM, Nelson RA, Simon MS, Irwin ML, Neuhouser ML, Reding KW, Crane TE, Manson JE, Nassir R, Shadyab AH, LaMonte M, Qi L, Thomson CA, Kroenke CH, Pan K, Chlebowski RT, Mortimer J. Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women’s Health Initiative. BMC Women's Health 2022, 22: 32. PMID: 35120497, PMCID: PMC8817588, DOI: 10.1186/s12905-022-01614-3.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityCancer-specific mortalityWomen's Health Initiative participantsEarly-stage breast cancerCardiometabolic risk factorsBreast cancer mortalityPhysical activity levelsRisk factor numberPhysical activityBreast cancerRisk factorsCancer mortalityHigher breast cancer-specific mortalityLower breast cancer-specific mortalityInitiative participantsHealth initiativesNational Death Index queryProportional hazards regression modelsHigher physical activity levelsCancer diagnosisMetabolic syndrome componentsBaseline physical activityHigh waist circumferenceMedical record reviewCause mortality risk
2021
Factors associated with late risks of breast cancer-specific mortality in the SEER registry
Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research And Treatment 2021, 189: 203-212. PMID: 33893907, PMCID: PMC8302525, DOI: 10.1007/s10549-021-06233-4.Peer-Reviewed Original ResearchConceptsBC-specific mortalityHR-positive breast cancerHR-negative breast cancerBreast cancerHR statusCumulative riskBreast cancer-specific mortalityCancer-specific mortalityT1a/bHormone receptor statusYear of diagnosisKaplan-Meier analysisLong-term riskBC deathConclusionThe risksGray regressionN2 diseaseLate relapseReceptor statusLate recurrenceSEER registryLater riskClinical trialsYear 5PatientsTwenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2019
Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. DOI: 10.1200/jco.2019.37.15_suppl.540.Peer-Reviewed Original ResearchRisk of BCSMBreast cancer-specific mortalityHR- breast cancerBreast cancerAdjusted riskCumulative riskAnnual event rateCancer-specific mortalityHormone receptor statusBreast cancer deathsEnd Results registryBetter adjuvant therapyKaplan-Meier analysisLong-term riskLate deathsAdjuvant therapyLate relapseReceptor statusHR statusPrimary cancerCox regressionBaseline variablesBlack raceCancer deathClinical trials
2018
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalence
2017
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Research And Treatment 2017, 164: 107-117. PMID: 28364214, PMCID: PMC5479131, DOI: 10.1007/s10549-017-4222-8.Peer-Reviewed Original ResearchConceptsOlder breast cancer patientsLong-term mortalityBreast cancer patientsCancer patientsHormonal therapyRobust patientsFrailty indexBreast cancer-specific mortalityDeficit-accumulation frailty indexAbsolute mortality differencePurposeBreast cancer patientsAdjusted hazard ratioCancer-specific mortalityBreast cancer deathsInvasive breast cancerBreast cancer mortalityAdjusted hazardFrailty categoriesCause mortalityFrail patientsMore chemotherapyFrailty statusHazard ratioOlder patientsClinical factorsExercise, metabolic syndrome, and cardiovascular fitness in breast cancer survivors.
Knobf M, Sinusas A, Holland M, Jeon S. Exercise, metabolic syndrome, and cardiovascular fitness in breast cancer survivors. Journal Of Clinical Oncology 2017, 35: 165-165. DOI: 10.1200/jco.2017.35.5_suppl.165.Peer-Reviewed Original ResearchBreast cancer survivorsPhysical activity groupHeart rate recoveryMetabolic syndromeCancer survivorsLifestyle behaviorsCardiovascular diseaseRate recoveryCardiovascular fitnessAge-matched postmenopausal womenBreast cancer-specific mortalityActivity groupHigh baseline incidenceCancer-specific mortalityFirst-line interventionCause mortalityEndocrine therapyPostmenopausal womenExercise interventionMetS componentsMetS criteriaDiastolic BPSystolic BPMonths interventionMetabolic outcomes
2015
Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis
Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. Journal Of The National Cancer Institute 2015, 107: djv275. PMID: 26424778, PMCID: PMC4715249, DOI: 10.1093/jnci/djv275.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancer-specific mortalityCancer-specific mortalityCause mortalityWeight gainBreast cancer diagnosisBreast cancerStage I-IIIC breast cancerSystematic reviewPrediagnosis body mass indexWomen age 18 yearsPostdiagnosis weight gainCancer diagnosisCause mortality ratesBreast cancer mortalityAge 18 yearsWeb of ScienceCohort studyRecurrence outcomesMass indexCancer mortalityClinical trialsHigh riskMortality rateBody weight
2011
Physical Activity and Survival in Postmenopausal Women with Breast Cancer: Results from the Women's Health Initiative
Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, Wactawski-Wende J, Craft L, Lane D, Martin LW, Chlebowski R. Physical Activity and Survival in Postmenopausal Women with Breast Cancer: Results from the Women's Health Initiative. Cancer Prevention Research 2011, 4: 522-529. PMID: 21464032, PMCID: PMC3123895, DOI: 10.1158/1940-6207.capr-10-0295.Peer-Reviewed Original ResearchConceptsCause mortalityPostmenopausal womenPhysical activityBreast cancerMore MetHealth initiativesLower breast cancer mortalityBreast cancer-specific mortalityWomen's Health Initiative studyActive breast cancer survivorsCancer-specific mortalityInvasive breast cancerLow physical activityBreast cancer survivorsMultivariable adjusted analysesWomen's Health InitiativeBreast cancer mortalityAdjusted analysisCancer survivorsCancer mortalityInactive womenInitiative studyMortalityCancerDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply